The earnings call highlighted positive aspects such as increased LAL revenue, improved gross margin, and international market expansion. However, significant challenges were noted including overall revenue decline, decreased LDD sales, increased net loss, and higher operating expenses. The guidance for a revenue decline further contributed to the cautious outlook.

Company Guidance -

Q3 2025

In the recent call, RxSight reiterated its full-year 2025 guidance with expectations of total revenue between $120 million to $130 million, indicating a decrease of 7% to 14% from 2024. The company projects gross margins of 72% to 74%, an increase of 130 to 330 basis points compared to last year, despite a first-half gross margin nearing 75%. Operating expenses are anticipated to rise by 7% to 14%, ranging from $145 million to $155 million, which includes noncash stock-based compensation costs of $27 million to $30 million. The guidance reflects a cautious outlook, taking into account ongoing challenges in LAL adoption and a reduction in new LDD sales. Additionally, RxSight is focusing on improving customer engagement and clinical support to drive long-term growth, while strategically expanding into international markets to enhance revenue potential beyond 2025.

Increase in LAL Revenue

LAL revenue for the second quarter of 2025 was $27 million, up 13% compared to the second quarter of 2024 and representing 80% of total revenue, an increase from 68% in the second quarter of 2024.

Improvement in Gross Margin

Gross margin in the second quarter of 2025 was 74.9%, up from 69.5% in the year ago period, reflecting a favorable shift in product mix towards higher-margin LAL revenue.

LDD Installed Base Growth

The LDD installed base totaled 1,084 units as of June 30, 2025, representing a 34% increase year-over-year.

Expansion in International Markets

RxSight has received regulatory approval in South Korea and launched operations in Q2 2025, with a focus on building out the European team following MDR certification.

RxSight (RXST) Earnings, Revenues Date & History

The upcoming earnings date is based on a company’s previous reporting, and may be updated when the actual date is announced

Daily Earnings Calendar >

RXST Earnings History

Report Date	Fiscal Quarter	Forecast / EPS	Last Year's EPS	EPS YoY Change	Slides	Play Transcript
Nov 06, 2025	2025 (Q3)	-0.37 / -	-0.16	―	―	―
Aug 07, 2025	2025 (Q2)	-0.25 / -0.29	-0.16	-81.25% (-0.13)	―
May 07, 2025	2025 (Q1)	-0.22 / -0.20	-0.25	20.00% (+0.05)	―
Feb 25, 2025	2024 (Q4)	-0.17 / -0.15	-0.26	42.31% (+0.11)	―
Nov 07, 2024	2024 (Q3)	-0.25 / -0.16	-0.35	54.29% (+0.19)	―
Aug 05, 2024	2024 (Q2)	-0.22 / -0.16	-0.4	60.00% (+0.24)	―
May 06, 2024	2024 (Q1)	-0.29 / -0.25	-0.42	40.48% (+0.17)	―
Feb 28, 2024	2023 (Q4)	-0.37 / -0.26	-0.56	53.57% (+0.30)	―
Nov 09, 2023	2023 (Q3)	-0.43 / -0.35	-0.61	42.62% (+0.26)	―
Aug 07, 2023	2023 (Q2)	-0.47 / -0.40	-0.61	34.43% (+0.21)	―

The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.

Beat

Missed

RXST Earnings-Related Price Changes

Report Date	Price 1 Day Before	Price 1 Day After	Percentage Change
Aug 07, 2025	$7.79	$7.19	-7.70%
May 07, 2025	$14.90	$13.23	-11.21%
Feb 25, 2025	$29.21	$28.97	-0.82%
Nov 07, 2024	$50.85	$48.01	-5.59%

Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.

FAQ

When does RxSight (RXST) report earnings?

RxSight (RXST) is schdueled to report earning on Nov 06, 2025, After Close (Confirmed).

What is RxSight (RXST) earnings time?

RxSight (RXST) earnings time is at Nov 06, 2025, After Close (Confirmed).

Where can I see when companies are reporting earnings?

You can see which companies are reporting today on our designated earnings calendar.

What companies are reporting earnings today?

You can see a list of the companies which are reporting today on TipRanks earnings calendar.

What is RXST EPS forecast?

RXST EPS forecast for the fiscal quarter 2025 (Q3) is -0.37.

Become an Expert with TipRanks Premium

What am I Missing?

Make informed decisions based on Top Analysts' activity

Know what industry insiders are buying

Get actionable alerts from top Wall Street Analysts

Find out before anyone else which stock is going to shoot up

Get powerful stock screeners & detailed portfolio analysis

Subscribe Now See Plans & Pricing